Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 115

1.

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.

IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC.

Ophthalmology. 2012 Jul;119(7):1399-411. doi: 10.1016/j.ophtha.2012.04.015. Epub 2012 May 11. Erratum in: Ophthalmology. 2013 Sep;120(9):1719. Ophthalmology. 2012 Aug;119(8):1508.

PMID:
22578446
[PubMed - indexed for MEDLINE]
2.

Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.

Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G; GEFAL Study Group.

Ophthalmology. 2013 Nov;120(11):2300-9. doi: 10.1016/j.ophtha.2013.06.020. Epub 2013 Aug 2.

PMID:
23916488
[PubMed - indexed for MEDLINE]
3.

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.

Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd.

Ophthalmology. 2012 Jul;119(7):1388-98. doi: 10.1016/j.ophtha.2012.03.053. Epub 2012 May 1.

PMID:
22555112
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial.

Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, Reeves BC; IVAN study investigators.

Lancet. 2013 Oct 12;382(9900):1258-67. doi: 10.1016/S0140-6736(13)61501-9. Epub 2013 Jul 19.

PMID:
23870813
[PubMed - indexed for MEDLINE]
Free Article
5.

Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.

Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS.

Cochrane Database Syst Rev. 2014 Aug 29;8:CD005139. doi: 10.1002/14651858.CD005139.pub3. Review.

PMID:
25170575
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.

Stein JD, Newman-Casey PA, Mrinalini T, Lee PP, Hutton DW.

Ophthalmology. 2014 Apr;121(4):936-45. doi: 10.1016/j.ophtha.2013.10.037. Epub 2014 Jan 7.

PMID:
24405740
[PubMed - indexed for MEDLINE]
7.

Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study.

Jackson TL, Chakravarthy U, Kaiser PK, Slakter JS, Jan E, Bandello F, O'Shaughnessy D, Gertner ME, Danielson L, Moshfeghi DM; INTREPID Study Group.

Ophthalmology. 2013 Sep;120(9):1893-900. doi: 10.1016/j.ophtha.2013.02.016. Epub 2013 Mar 13.

PMID:
23490327
[PubMed - indexed for MEDLINE]
8.

Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration.

Ying GS, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, Daniel E, Klein M, Pieramici D, Wells J, Martin DF; Comparison of Age-related Macular Degeneration Treatments Trials Research Group.

Ophthalmology. 2013 Jan;120(1):122-9. doi: 10.1016/j.ophtha.2012.07.042. Epub 2012 Oct 6.

PMID:
23047002
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U; VIEW 1 and VIEW 2 Study Groups.

Ophthalmology. 2012 Dec;119(12):2537-48. doi: 10.1016/j.ophtha.2012.09.006. Epub 2012 Oct 17. Erratum in: Ophthalmology. 2013 Jan;120(1):209-10.

PMID:
23084240
[PubMed - indexed for MEDLINE]
10.

How the comparison of age-related macular degeneration treatments trial results will impact clinical care.

Davis J, Olsen TW, Stewart M, Sternberg P Jr.

Am J Ophthalmol. 2011 Oct;152(4):509-14. doi: 10.1016/j.ajo.2011.07.004.

PMID:
21961847
[PubMed - indexed for MEDLINE]
11.

Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.

Brown DM, Chen E, Mariani A, Major JC Jr; SAVE Study Group.

Ophthalmology. 2013 Feb;120(2):349-54. doi: 10.1016/j.ophtha.2012.08.008. Epub 2012 Nov 3.

PMID:
23131717
[PubMed - indexed for MEDLINE]
12.

Bevacizumab for neovascular age-related macular degeneration in China.

Li X, Hu Y, Sun X, Zhang J, Zhang M; Neovascular Age-Related Macular Degeneration Treatment Trial Using Bevacizumab (NATTB).

Ophthalmology. 2012 Oct;119(10):2087-93. doi: 10.1016/j.ophtha.2012.05.016. Epub 2012 Jul 20.

PMID:
22818896
[PubMed - indexed for MEDLINE]
13.

Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.

Busbee BG, Ho AC, Brown DM, Heier JS, Suñer IJ, Li Z, Rubio RG, Lai P; HARBOR Study Group.

Ophthalmology. 2013 May;120(5):1046-56. doi: 10.1016/j.ophtha.2012.10.014. Epub 2013 Jan 23.

PMID:
23352196
[PubMed - indexed for MEDLINE]
Free Article
14.

The SECURE study: long-term safety of ranibizumab 0.5 mg in neovascular age-related macular degeneration.

Silva R, Axer-Siegel R, Eldem B, Guymer R, Kirchhof B, Papp A, Seres A, Gekkieva M, Nieweg A, Pilz S; SECURE Study Group.

Ophthalmology. 2013 Jan;120(1):130-9. doi: 10.1016/j.ophtha.2012.07.026. Epub 2012 Sep 25.

PMID:
23021093
[PubMed - indexed for MEDLINE]
15.

Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.

Dunavoelgyi R, Sacu S, Eibenberger K, Palkovits S, Leydolt C, Pruente C, Schmidt-Erfurth U.

Retina. 2012 Sep;32(8):1471-9. doi: 10.1097/IAE.0b013e318236e805.

PMID:
22414958
[PubMed - indexed for MEDLINE]
16.

Bevacizumab in age-related macular degeneration: a randomized controlled trial on the effect of injections every 4 weeks, 6 weeks and 8 weeks.

Lushchyk T, Amarakoon S, Martinez-Ciriano JP, van den Born LI, Baarsma GS, Missotten T.

Acta Ophthalmol. 2013 Sep;91(6):e456-61. doi: 10.1111/aos.12119. Epub 2013 Jun 15.

PMID:
23773796
[PubMed - indexed for MEDLINE]
17.

Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact.

Shienbaum G, Gupta OP, Fecarotta C, Patel AH, Kaiser RS, Regillo CD.

Am J Ophthalmol. 2012 Mar;153(3):468-473.e1. doi: 10.1016/j.ajo.2011.08.011. Epub 2011 Oct 11.

PMID:
21996309
[PubMed - indexed for MEDLINE]
18.

Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial.

Subramanian ML, Ness S, Abedi G, Ahmed E, Daly M, Feinberg E, Bhatia S, Patel P, Nguyen M, Houranieh A.

Am J Ophthalmol. 2009 Dec;148(6):875-82.e1. doi: 10.1016/j.ajo.2009.07.009. Epub 2009 Oct 2.

PMID:
19800611
[PubMed - indexed for MEDLINE]
19.

Bevacizumab and ranibizumab for neovascular age-related macular degeneration: a treatment approach based on individual patient needs.

Bellerive C, Cinq-Mars B, Lalonde G, Malenfant M, Tourville E, Tardif Y, Giasson M, Hébert M.

Can J Ophthalmol. 2012 Apr;47(2):165-9. doi: 10.1016/j.jcjo.2012.01.011.

PMID:
22560423
[PubMed - indexed for MEDLINE]
20.

A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration.

Krebs I, Schmetterer L, Boltz A, Told R, Vécsei-Marlovits V, Egger S, Schönherr U, Haas A, Ansari-Shahrezaei S, Binder S; MANTA Research Group.

Br J Ophthalmol. 2013 Mar;97(3):266-71. doi: 10.1136/bjophthalmol-2012-302391. Epub 2013 Jan 3.

PMID:
23292928
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk